Annual Reports

Quarterly Reports


  • 8-K (Jan 9, 2009)
  • 8-K (Nov 13, 2008)
  • 8-K (Nov 3, 2008)
  • 8-K (Oct 30, 2008)
  • 8-K (Oct 7, 2008)
  • 8-K (Sep 4, 2008)


Genelabs Technologies 8-K 2007

Documents found in this filing:

  1. 8-K
  2. 8-K



Washington, D.C. 20549





Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 26, 2007


Genelabs Technologies, Inc.

(Exact Name of Registrant as Specified in its Charter)






(State or other jurisdiction
of incorporation)


File Number)


(IRS Employer
Identification No.)


505 Penobscot Drive, Redwood City, California



(Address of principal executive offices)


(Zip Code)

Registrant’s telephone number, including area code: (650) 369-9500


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR   230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR   240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the   Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the   Exchange   Act (17 CFR 240.13e-4(c))






Item 5.02. Compensatory Arrangements of Certain Officers.


On January 26, 2007, Genelabs Technologies, Inc.’s (the “Registrant”) board of directors (the “Board”), taking into account the recommendation of the compensation committee of the Board, increased the annual base salary of Dr. Ronald Griffith, the Registrant’s chief scientific officer, by $13,000 to $300,000. The Registrant’s board of directors, taking into account the recommendations of the compensation committee of the Board, also approved an increase in the annual base salary of Dr. Irene Chow, the Registrant’s chairman of the Board, by $140,000 to $350,000 and a 2007 fiscal year retention bonus to Dr. Chow of $200,000, payable in two equal installments on March 31, 2007 and June 30, 2007, provided that Dr. Chow is a member of the Board and/or an employee of the Registrant on such dates.







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Genelabs Technologies, Inc.

Date: February 1, 2007




/s/ James A.D. Smith




James A.D. Smith




President and Chief Executive Officer







Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki